Nanomedicines for kidney diseases.
Nanomedicines have been the subject of great interest for the treatment, diagnosis, and research of disease; however, few specifically address kidney disorders. Nanotechnology can confer significant benefits to medicine, such as the targeted delivery of drugs to specific tissues. Nanomedicines in the clinic have increased drug solubility, reduced off-target side effects, and provided novel diagnostic tools. There is an increasing cohort of nanomaterials that may have implications for kidney disease. Here, we review nanomaterial properties that are potentially applicable to kidney research and therapy, and we highlight clinical areas of need that may benefit from kidney nanomedicines.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ryan M
RM
Williams
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA. Electronic address: jaimese@mskcc.org.
Edgar A
EA
Jaimes
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA. Electronic address: hellerd@mskcc.org.
Daniel A
DA
Heller
D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000628:therapy*; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry / Q000627:therapeutic use*; D065667:Renal Elimination
diagnostics; drug development; imaging; nanoparticles; theranostics; therapeutics